MicroRNA-409-3p Functions as a Tumor Suppressor in Human Lung Adenocarcinoma by Targeting c-Met

Li Wan, Lingjun Zhu, Jianghao Xu, Binbin Lu, Yucai Yang, Fengzhen Liu, Zhaoxia Wang

Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China

Key Words
miR-409-3p • c-Met • prognosis • Lung adenocarcinoma • Tumor suppressor

Abstract
Background/Aims: Dysregulation of microRNAs is correlated with tumor development. The aim of this study is to investigate the clinicopathologic and prognostic significance of microRNA (miR)-409-3p and its tumor suppressor roles in lung adenocarcinoma (LAD).

Methods: Quantitative real-time PCR (qRT-PCR) was performed to detect miR-409-3p expression in LAD tissues and corresponding noncancerous tissues. Additionally, the correlations of miR-409-3p expression with clinicopathologic factors and prognosis of patients were statistically analyzed. Next, we investigated whether miR-409-3p could function as a tumor suppressor in LAD cells via regulation of Akt signaling by targeting receptor tyrosine kinase (c-Met).

Results: MiR-409-3p was significantly downregulated in LAD tissues compared with corresponding noncancerous tissues. Low miR-409-3p expression was observed to be significantly correlated with poorer tumor differentiation, advanced pTNM stage and higher incidence of lymph node metastasis. Multivariate Cox regression analyses showed that miR-409-3p expression was an independent prognostic factor for LAD patients. Functional analyses indicated that miR-409-3p could inhibit growth, induce apoptosis, reduce migration and invasion in LAD cells via inactivation of Akt signaling by targeting c-Met.

Conclusions: MiR-409-3p was an independent prognostic factor and functioned as a tumor suppressor in LAD via regulation of Akt signaling by targeting c-Met.
Introduction

Lung cancer, one of the most common malignancies around the world, is the leading cause of cancer death worldwide [1]. In China, about 300,000 new lung cancer patients and more than 250,000 deaths from the disease are predicted each year. Adenocarcinoma of the lung is the most common type of lung cancer and accounts for 30 to 35 percent of primary lung tumors. Recent advances in the multidisciplinary management of the disease, including surgery, chemoradiotherapy and molecular-targeted therapy, but a substantial proportion of LAD patients with localized or locally advanced disease will eventually die [2]. Lung carcinogenesis is a complex multistep process involving genetic dysregulation of proto-oncogenes and tumor suppressor genes [3]. Therefore, a better understanding of molecular mechanisms underlying LAD development will contribute to identifying novel prognostic markers and molecular therapeutic targets for human LAD.

MicroRNAs (miRNAs), a class of small non-coding RNAs, can function post-transcriptionally through imperfect base pairing with specific sequences in the 3’ untranslated regions (UTRs) of target mRNAs leading to transcript degradation or translational inhibition [4, 5]. Emerging evidence indicates that dysregulation of miRNAs is involved in many human biological and pathological processes, such as cell proliferation, differentiation, development, apoptosis, and tumorigenesis [6-8]. It has been revealed that miRNAs function in various stages of cancer development, showing that abnormal miRNA expressions play critical roles in modulating expression of known oncogenes or tumor suppressor genes during cancer progression [9]. Recently, the correlation of dysregulation of miRNAs with LAD is increasingly reported. By high-throughput sequencing combined with differential expression analysis, Xie’ et al identified that 7 microRNAs were down-regulated and 21 microRNAs were up-regulated in LAD with bone metastasis [10]. By performing microRNA expression profiles of whole blood in lung adenocarcinoma, Patnaik and his colleagues showed that four microRNAs (miR-190b, miR-630, miR-942, and miR-1284) were the most frequent constituents of the classifiers generated during the analyses, suggesting that whole blood microRNA expression profiles can be used to distinguish lung cancer cases from clinically relevant controls [11]. Additionally, Zhang’ et al reported that circulating miR-195 and miR-122 may have prognostic values in predicting the overall survival as well as predicting EGFR mutation status in non-smoking female patients with lung adenocarcinoma, suggesting that measuring plasma levels of miR-195 and miR-122 may especially be useful in EGFR mutant patients with lung adenocarcinoma [12]. These data suggest that dysregulation of miRNAs may play important roles in LAD progression and development. Previously, miR-409-3p has been reported to inhibit growth, invasion and metastasis of tumor cells, including bladder cancer, gastric cancer and fibrosarcoma [13-15]. However, expression of miR-409-3p and its clinicopathologic or prognostic significance in LAD are not fully understood. In addition, the roles of miR-409-3p in LAD development and its possible molecular mechanisms remain to be further elucidated.

In the present study, we show that downregulation of miR-409-3p in LAD is correlated with an aggressive phenotype and poor prognosis of patients. Further investigations indicated that miR-409-3p directly targeted the 3’-UTRs of receptor tyrosine kinase c-Met, which functions as an oncogene in LAD, to suppress its expression, which in turn led to the inhibition of growth or invasion in LAD cells. Thus, miR-409-3p is a good prognostic factor for LAD patients and functions as a tumor suppressor in human LADs.

Materials and Methods

Ethics statement

Human LAD and matched non-cancerous tissues were collected after obtaining written informed consent from all patients. The study was approved by the Institutional Review Board of Nanjing Medical University.
Cell lines and culture

A normal human bronchial epithelial cell line (HBE) and three LAD cell lines (A549, SPC-A1 and PC9) were purchased from Shanghai Institute Chinese academy of science and cultured in RPMI 1640 media (Invitrogen, CA, USA) supplemented with 10% fetal bovine serum (FBS) and 100 μM each of penicillin and streptomycin in a humidified atmosphere of 5% CO₂ at 37°C.

Patients and tissue samples

Fresh LAD and matched adjacent normal tissue specimens were collected from 128 patients who underwent surgery after removal of the necessary amount of tissue for routine pathology examination at the Department of Chest Surgery of the First or Second Affiliated Hospital of Nanjing Medical University. Samples were snap-frozen in liquid nitrogen and stored at -80°C until RNA extraction. Diagnosis of LAD was determined according to the latest World Health Organization (WHO) criteria and TNM stage classification (UICC 2002). Related clinical data were collected, including gender, age, smoking history, tumor differentiation, pTNM stage, lymph node metastasis, and 5-year follow-up survival. All patients did not receive chemotherapy or radiotherapy prior to surgery. Patient characteristics are shown in Table 1. Pathologic staging was performed in accordance to the current International Union Against Cancer tumor-lymph node-metastasis classification. Written informed consent was obtained from all patients. The ethics committee of Jiangsu Province Medical Association approved the study protocol.

RNA isolation and qRT-PCR assay

Total RNA was isolated from cells using Trizol (Invitrogen), and 2 μl RNA (1μg/μl) was used to synthesize cDNA with Super-Script II First-Strand Synthesis System (Invitrogen) or TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems). Aliquots of the reaction mixture were used for real-time PCR with Power SYBR Green PCR Master Mix or with the TaqMan® 2 × Universal PCR Master Mix. The reaction conditions: 50°C for 20 s, 95°C for 10 min followed by 40 cycles of 95°C for 15 s, 60°C for 1 min. We calculated a ΔΔCt (target-reference), which is equal to the difference between threshold cycles for miR-409-3p (ie, target) and the threshold cycle for U6 RNA (ie, reference) (ie, ΔΔCt (target-reference)=Ct target-Ct reference). The fold-change between patient or cell sample and a normal control for miR-409-3p or c-Met was calculated with the 2⁻ΔΔCt method. All real-time PCR experiments were performed in triplicate.

Transfection of oligonucleotides and plasmid vectors

The pGCMV/EGFP/miRNA vectors with and without human miR-409-3p expression (pGCMV/miR-409-3p and pGCMV/miRNA-NC), miR-409-3p mimics or inhibitor (anti-miR-409-3p) and their control oligonucleotides (anti-miRNA-NC) were obtained from GenePharma (Shanghai, China). For c-Met interfering, DNA template oligonucleotides corresponding to c-Met (accession number NM_000245) were synthesized as follows: c-Met-shRNA1 (sense, 5'-GATCCGCGCCAC-CTACAGAAATGGTTTCAAGAGAACATTCTGTAGTTGGGCA GA-3'), c-Met-shRNA2 (sense, 5'-GATCCAAGTGGCACTATCCTCTCTGACTTCAAGAGAGTCAGAGGATACTGCACTTAGA-3') and a non-specific shRNA, control-shRNA (sense, 5'-GATCTAAGCACTTGAACGATCGACTTTCAAGAAGGATTGCTGTA-3'). The above sequences were inserted into the BglII and HindIII restriction endonuclease sites of pSUPER.retro vector, respectively. Those recombinant plasmids were named pSUPER-shRNA/control (shRNA/control), pSUPER-shRNA/c-Met1(shRNA/c-Met1), and pSUPER-shRNA/c-Met2 (shRNA/c-Met2) vector, respectively. For ectopic expression of c-Met, the open reading frame of c-Met that was generated by PCR using the following primers: sense 5'-CGCTCGAGAGTGGGCAGAGGAATGCCTG-3'; reverse 5'-GCGGATCCCGAAGGAGAGCTCGAGGACTGC-3', and then inserted into the pcDNA 3.1(+) expression vector which was named pcDNA/c-Met. Those recombinant vectors were confirmed by the digestion analysis of restriction endonuclease and all inserted sequences were verified by DNA sequencing. The vectors were performed using Lipofectamine™ 2000 (Invitrogen, USA) according to the instructions provided by the manufacturer. Stable cell lines expressing pri-miR-409-3p were selected with G418 (400 mg/ml) and colonies stably expressing shRNAs were selected with 8.0 µg/ml puromycin (Sigma, USA).

Western blotting assay

Cells or tissues were washed with cold phosphate-buffered saline solution, and total proteins were extracted in the extraction buffer (150mM sodium chloride; 50mMTris hydrochloride, pH7.5;1%glycerol; and 1%Non-identp-40 substitute solution). Equal amounts of protein (15μg per lane) from the treated cells...
were loaded and electrophoresed on an 8% sodium dodecyl sulfate (SDS) polyacrylamide gel and then electroblotted onto nitrocellulose membrane, blocked by 5% skim milk, and probed with the antibodies to c-Met, phosphorylated c-Met (p-c-Met), cleaved caspase-3, total caspase-3, cleaved PARP, total PARP, phosphorylated AKT (Ser473), total Akt, Bcl-2, Bax, MMP-2, MMP-9 and GAPDH (Santa Cruz Biotechnology, Santa Cruz, California, USA), followed by treatment with secondary antibody conjugated to horseradish peroxidase. The proteins were detected by the enhanced chemiluminescence system and exposed to x-ray film. Band density was measured by photoimage analysis using the Quantity one software (Bio-Rad, Hercules, CA, USA), and expressed as the percentage of density of the respective housekeeping GAPDH.

**3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay**

The cell viability was measured by MTT assay (Sigma, USA). In brief, the cells were seeded into five 96-well culture plates with each plate having all four kinds of A549 cells transiently transfected with miR-409-3p mimics (miR-NC mimics) or anti-miR-409-3p (anti-miR-NC) (6-parallel wells/group). On each day, 200 μL MTT (5 mg/mL) was added to each well, and the cells were incubated for at 37°C for additional 4h. Then the reaction was stopped by lysing the cells with 150 μL DMSO for 5 min. Optical densities were determined on a Versamax microplate reader (Molecular Devices, Sunnyvale, CA, USA) at 490 nm.

**Colony formation assay**

The A549 cells stably transfected with pGCMV/miR-409-3p or pGCMV/miR-NC were trypsinized to single cell suspensions and were seeded 6-well plates at 500/well. After 14 days culture RPMI 1640 medium, the colonies were stained with Giemsa solution and the number of colonies was counted. Each experiment was performed in triplicate.

**Flow cytometric analysis of apoptosis**

The cells were harvested, washed twice with cold PBS, fixed in ice-cold 70% ethanol, and incubated overnight at -20°C. Then, cells were stained with 40 µg/mL of propidium iodide (PI) for 30 min. The minimum of 1.0×10^6 cells were collected and analyzed by software Cell Quest (Becton Dickinson Co., NJ, USA). The percentage of cells with apoptotic nuclei (% apoptosis) was calculated.

**Wound healing assay**

The cells were seeded into 24-well tissue culture plates. 48h later, an artificial homogenous wound was created onto the monolayer with a sterile plastic 100 μL micropipette tip. After wounding, the debris was removed by washing the cells with serum-free medium. Migration of cells into the wound was observed at different time points. Cells that migrated into the wounded area or cells with extended protrusion from the border of the wound were visualized and photographed under an inverted microscope. A minimum of five randomly chosen areas were measured and the distance of cell migration to the wound area was determined.

**Transwell invasion assay**

Transwell invasion assays were performed with 6-well matrigel-coated chambers from BD Biosciences (Bedford, MA, USA). In brief, the cells were seeded into inserts at 05.0×10^4/insert in serum-free medium and then transferred to wells filled with the culture medium containing 10% FBS as a chemoattractant. After 24h of incubation, non-invading cells on the top of the membrane were removed by scraping. Invaded cells on the bottom of the membrane were fixed, followed by staining with 0.05% crystal violet. The number of invaded cells on the membrane was then counted under a microscope.

**Luciferase activity assay**

To testify the validation of c-Met as a direct target of miR-409-3p, we performed miRNA target luciferase reporter assay using a pEZX-MT01 target reporter plasmid containing c-Met/3’-UTR (Genecoepia, Rockville, MD). Additionally, we generated mutant c-Met/3’-UTR reporter construct (pEZX-Luc-c-Met/3’-UTR-mut) by site-directed mutagenesis in the putative target site of miR-409-3p in the wild-type c-Met/3’-UTR (pEZX-Luc-c-Met/3’-UTR-wt) using Stratagene QuikChange® Site-Directed Mutagenesis Kit (Stratagene, Heidelberg, Germany). The cells were transiently cotransfected for 24 h with reporter plasmids (200 ng) and 100 nM of miR-409-3p mimics or inhibitor and harvested in reporter lysis buffer. Both firefly luciferase
and Renilla luciferase activities were measured using the Dual-Luciferase assay kit (Promega, Madison, WI) according to manufacturer’s instructions. The luciferase activity normalized against protein concentration was expressed as a ratio of firefly luciferase to Renilla luciferase unit.

Statistical analysis

Statistical analysis was performed with SPSS version 13.0 (SPSS Inc., Chicago, IL). Values are expressed as the mean±SD. The relationship between miR-409-3p expression and clinicopathologic factors was analyzed by Pearson’s chi-squared test. Survival curves were plotted by the Kaplan-Meier method and compared using the log-rank test. Survival data were evaluated using univariate and multivariate Cox regression analyses. The correlation between the miR-409-3p expression level and the protein level of c-Met was evaluated by Spearman’s rank correlation coefficients. \( P<0.05 \) was considered statistically significant.

Results

**MiR-409-3p is downregulated in primary LAD tissues**

First, qRT-PCR assay was performed to detect the expression levels of miR-409-3p in 34 pairs of human LAD tissues and their matched adjacent non-cancerous tissues, and the results indicated that miR-409-3p was significantly downregulated in 79.4\% (27/34) of the LAD tissues examined in comparison with the matched adjacent non-cancerous tissues from the same group of patients (Fig. 1A). Also, we detected the expression of miR-409-3p in a normal human bronchial epithelial cell line (HBE) and three LAD cell lines (A549, SPC-A1 and H1299), and showed that the relative expression level of miR-409-3p in LAD cell lines was significantly lower than that in normal human bronchial epithelial cell line (Fig. 1B). By statistical analyses, it was shown that the miR-409-3p expression levels were significantly lower in the LAD tissues than the matched adjacent non-cancerous tissues \( (P=0.013; \) Fig. 1C). Also, we detected the expression of miR-409-3p in tumors with various pTNM stage, and results showed that miR-409-3p was expressed at relatively high levels in tumors with an early pTNM stage (pl and pII), and significantly downregulated in pIII tumors and further downregulated in pIV tumors (Fig. 1D). Also, the expression of miR-409-3p in LAD tissues with or without lymph node metastasis was analyzed. Results indicated that the miR-409-3p expression levels were significantly lower in tumors with lymph node metastasis than those without lymph node metastasis \( (P=0.007; \) Fig. 1E). Thus, these data indicated that lower miR-409-3p expression might be involved in LAD development.
Fig. 1. The expression levels of miR-409-3p in LAD tissues. (A) qRT-PCR assay was performed to detect the relative expression of mature miR-409-3p in 34 LAD and corresponding non-cancerous tissues. (B) qRT-PCR detection of miR-409-3p expression in three LAD cell lines (A549, SPC-A1 and PC9). U6 was used as an internal control. (C) Calculating the mean level of miR-409-3p in 34 cases of LAD tissues (T) and corresponding noncancerous tissues (N), respectively (P=0.013). (D) Detection of miR-409-3p expression in tumor tissues with various pTNM stage (pI, pII, pIII and pIV). (E) Detection of miR-409-3p expression in metastatic and nonmetastatic LAD tissues. The mean and standard deviation of expression levels relative to U6 expression levels are shown and are normalized to the expression in the normal tissue of each matched pair. Each experiment was performed at least in triplicate. *P<0.05, **P<0.01.

Table 2. Univariate and multivariate analysis of prognostic factors in LAD for 5-year OS. *P<0.05. Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; OS, overall survival. TNM, lymph-node-metastasis and stage according to the TNM classification for lung cancer (UICC)

<table>
<thead>
<tr>
<th>Clinicopathological factors</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95% CI)</td>
<td>P-value</td>
</tr>
<tr>
<td>Age (≥60 vs &lt;60 years)</td>
<td>1.88 (1.91-2.34)</td>
<td>0.268</td>
</tr>
<tr>
<td>Gender (Male vs Female)</td>
<td>2.11 (0.87-2.48)</td>
<td>0.167</td>
</tr>
<tr>
<td>Smoking (Smoker vs non-smoker)</td>
<td>1.23 (0.69-1.88)</td>
<td>0.312</td>
</tr>
<tr>
<td>Tumor differentiation</td>
<td>1.37 (0.71-1.65)</td>
<td>0.008*</td>
</tr>
<tr>
<td>(Poor vs Moderate vs Well)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pTNM stage (Stage III/IV vs Stage I/II)</td>
<td>2.78 (1.44-3.02)</td>
<td>0.016*</td>
</tr>
<tr>
<td>miR-409-3p expression (Low vs High)</td>
<td>1.76 (1.27-3.13)</td>
<td>0.006*</td>
</tr>
</tbody>
</table>

Correlation of miR-409-3p expression with clinicopathologic factors of LAD patients
To further investigate the correlation between miR-409-3p expression and clinicopathologic factors of LAD patient, the levels of miR-409-3p were quantified in...
another cohort of 84 LAD tissue samples using real-time RT-PCR. After normalization to U6 expression levels, the expression level of miR-409-3p in LAD tissues (mean±SD: 0.236±0.15) was significantly lower than that in adjacent normal tissues (mean±SD: 1.353±0.46, P<0.001). The median expression level of miR-409-3p (0.236) was used as a cutoff point to divide all 84 patients into two groups: LAD patients who express miR-409-3p at levels less than the cutoff value were assigned to the low expression group (mean expression value 0.158, n=38), and those with expression above the cutoff value were assigned to the high expression group (mean expression value 0.697, n=46). As shown in Table 1, statistical analyses indicated that low miR-409-3p expression in LAD was significantly correlated with poor tumor differentiation, advanced pTNM stage and higher incidence of lymph node metastasis (P=0.032, 0.028 and 0.020, respectively). However, there were no statistically significant correlation between miR-409-3p expression and other factors including age, gender, smoking condition, T-primary tumor and cancer-related death (P=0.744, 0.433, 0.071, 0.569 and 0.411, respectively).

**MiR-409-3p is an independent prognostic factor for LAD patients**

Next, we investigated the correlation of miR-409-3p expression with prognosis of LAD patients. Kaplan-Meier survival curves were plotted according to miR-409-3p expression, pTNM stage and status of lymph node metastasis. As shown in Fig. 2A, LAD patients with low-miR-409-3p expression had a lower recurrence-free survival than those patients with high-miR-409-3p expression (P=0.0008). As shown in Fig. 2B, LAD patients with high-miR-409-3p expression showed a better prognosis than those with low-miR-409-3p expression.
Wan et al.: MiR-409-3p: A Potential Tumor Suppressor in LAD Cellular Physiology and Biochemistry

The median survival time for the LAD patients with high-miR-409-3p was 52.4 months, and for LAD patients with low-miR-409-3p was 32.4 months. Also, we also found that patients with pTNM stage (pIII+IV) had shorter survival time than those with pTNM stage (pI+II) (P=0.0022; Fig. 2C). Additionally, LAD patients with lymph node metastasis had a shorter survival time than those with no lymph node metastasis (P=0.0108; Fig. 2D).

The data of univariate and multivariate analyses of factors correlated with prognosis of LAD patient were indicated in Table 2. By univariate survival analysis, it was observed that tumor differentiation, pTNM stage, and miR-409-3p expression were closely correlated with 5-year OS of LAD patients (P=0.008, 0.016 and 0.006, respectively). Further, multivariate Cox regression analyses showed that status of miR-409-3p, along with pTNM stage, was independent prognostic factors for LAD patients (P=0.038 and 0.026, respectively).

**MiR-409-3p inhibits growth and enhances apoptosis in LAD cells**

To better understanding the biological functions of miR-409-3p in the development of LAD, we first investigate the effect of miR-409-3p on growth and apoptosis of LAD cells. 48h After LAD cell line (A549) was transfected with miR-409-3p mimics or miR-409-3p inhibitor (anti-miR-409-3p), qRT-PCR was performed to detect the expression of miR-409-3p. U6 was used as an internal control. (B) MTT analysis of growth in A549 cells at different time points after transfection. (C) The colony formation assay was performed as described in Methods using A549 cells stably transfected with pGCMV/miR-409-3p or pGCMV/miR-NC. The number of colonies was counted and compared. (D) The apoptosis of A549 cells transfected with miR-409-3p mimics or control mimics was determined by flow cytometry. (E) Western blot analysis of the expression levels of cleaved caspase-3, total caspase-3, cleaved PARP and total PARP proteins. GAPDH was used as an internal control. Each experiment was performed at least in triplicate.*P<0.05, **P<0.01 versus control. N.S: not significance versus control.
A549 cells ($P<0.01$) and was significantly downregulated in anti-miR-409-3p-transfected cells ($P<0.05$). First, MTT assay indicated that transfection of miR-409-3p mimics could significantly inhibit growth but downregulation of miR-409-3p could moderately increase growth in A549 cells (Fig. 3B). Colony formation assay showed that the ability of colony formation in A549 cells stably transfected with pGCMV/miR-409-3p was significantly reduced in comparison with that in miR-NC mimics-transfected cells ($P<0.01$; Fig. 3C). In addition, transfection of miR-409-3p mimics induced apoptosis (14.56% versus 4.51% in the control group; $P<0.01$; Fig. 3D). Furthermore, the expression of cleaved caspase-3 and PARP proteins was significantly upregulated in miR-409-3p mimics-transfected A549 cells compared with miR-NC mimics-transfected cells (Fig. 3E). Likewise, we also confirmed that upregulation of miR-409-3p could inhibit growth and increase apoptosis in another LAD cell line (SPC-A1) (Fig. 4A-D). Collectively, miR-409-3p significantly inhibits the growth of LAD cells by promoting caspase-3-dependent apoptosis.

**MiR-409-3p inhibits in vitro migration and invasion in LAD cells**

Then, we will investigate the effect of miR-409-3p expression on migration and invasion of LAD cells. Wound healing assays showed that the migration of A549 cells was significantly decreased after transfection of miR-409-3p mimics (Fig. 5A). In contrast, anti-miR-409-3p increased wound healing (Fig. 5B). Similarly, in Matrigel invasion assays, upregulation of miR-409-3p could significantly reduce invasion of A549 cells (123 versus 412, $P<0.01$; Fig. 5C). Likewise, downregulation of miR-409-3p could markedly increase invasion of A549 cells.
Wan et al.: MiR-409-3p: A Potential Tumor Suppressor in LAD

Cellular Physiology and Biochemistry

(206 versus 354, \( P < 0.05 \); Fig. 5D). Likewise, we also confirmed that stable transfection of miR-409-3p could reduce migration and invasion in SPC-A1 cell line (Fig. 4E). These results suggest that miR-409-3p significantly inhibits \textit{in vitro} migration and invasion of LAD cells.

c-Met is identified as a direct target of miR-409-3p

To investigate the targets of miR-409-3p to elucidate the underlying mechanisms of its effects, we performed miRNA target gene prediction with PicTar, TargetScan and Miranda databases. The c-Met exhibited miR-409-3p-binding sequences in its 3'-UTR regions (Fig. 6A), and in silico analysis showed 3'-UTR of human c-Met (4912-4978 nt) contains a potential miR-409-3p binding site. To further confirm that the c-Met 3'-UTR is a target for miR-409-3p, we subcloned the fragment of c-Met 3'-UTR harboring the potential binding site into downstream of the pEZX-Luc vector to generate the pEZX-luc-c-Met/3'-UTR-wt vector and mutated the miR-409-3p binding site on c-Met 3'-UTR (c-Met/3'-UTR-mut) and subcloned it into pEZX-luc vector generate the pEZX-luc-c-Met/3'-UTR-mut vector. Those vectors were co-transfected into A549 cells with miR-409-3p mimics (or miR-NC mimics) or anti-miR-409-3p (or anti-miR-NC), and luciferase activity was determined. As shown in Fig. 6B, the luciferase activity was decreased by miR-409-3p mimics (\( P < 0.01 \)) when the wildtype c-Met/3'-UTR was present, and the activity was increased (\( P < 0.05 \)) when miR-409-3p was downregulated. However, the mutations of c-Met/3'-UTR prevented the expression of miR-409-3p from affecting luciferase activity. Next, we analyzed the effect of miR-409-3p expression on the expression of c-Met in LAD cells. As shown in Fig. 6C, transfection of miR-409-3p mimics could lead to the decreased expression of c-Met protein in A549 cells (\( P < 0.05 \)), while transfection of miR-409-3p inhibitor could lead to the increased expression
Wan et al.: MiR-409-3p: A Potential Tumor Suppressor in LAD

Cellular Physiology and Biochemistry

of c-Met protein \( (P<0.05) \). These data indicate that c-Met is a direct target of miR-409-3p in LAD.

**shRNA-mediated c-Met downregulation inhibits growth, induce apoptosis, reduce migration and invasion in LAD cells**

Previous studies have shown that c-Met (hepatocyte growth factor receptor), a tyrosine kinase receptor for hepatocyte growth factor (HGF), plays an important role in malignant transformation and tumor development by activating mitogenic signaling pathways [16, 17]. To better understand the biological functions of c-Met in LAD, shRNA/c-Met1 or 2 and shRNA/control vector was stably transfected into A549 cells, respectively. qRT-PCR and Western blot assays confirmed the downregulation of c-Met mRNA and protein induced by shRNA/c-Met1 or shRNA/c-Met2, and shRNA/c-Met2 exhibited the stronger inhibitory effect (Fig. 7A). Thus, shRNA/c-Met2 was chosen for further functional analyses. Results from MTT assay indicated that siRNA-mediated downregulation of c-Met could significantly inhibit growth of A549 cells and the highest inhibitory rate was 36.6±2.3% at 5 days \( (P<0.01; \) Fig. 7B). Compared with shRNA/control-transfected cells, the apoptotic rate of shRNA/c-Met2-transfected A549 cells was significantly increased by about 22.4% \( (P<0.01; \) Fig. 7C). Meanwhile, silencing of c-Met2 significantly increased the expression of cleaved caspase-3 and PARP proteins in A549 cells (Fig. 7D). Wound healing and Matrigel invasion assays indicated that shRNA/c-Met2 could significantly reduce the capacities of migration and invasion in A549 cells (Fig. 7E and F). These results suggest that shRNA-mediated downregulation of c-Met can mimic the effect of miR-409-3p upregulation on phenotypes of LAD cells.
Upregulation of c-Met partially rescues the effects of miR-409-3p on growth, apoptosis, migration and invasion in LAD cells

To further investigate the roles of c-Met in phenotypical changes of LAD cells induced by miR-409-3p, A549 cells were co-transfected with miR-409-3p mimics (or control mimics) and pcDNA/c-Met vector. 48h after co-transfection, Western blotting assay was performed to detect the expression of c-Met protein. As shown in Fig. 8A, the co-transfection could rescue the decreased expression of c-Met protein in A549 cells induced by miR-409-3p mimics.
Meanwhile, we found that overexpression of c-Met could reverse the inhibition of growth in A549 cells induced by miR-409-3p mimics (Fig. 8B). The enhancement of apoptosis and the increased expression of cleaved caspase-3 or PARP proteins in A549 cells induced by miR-409-3p mimics could also be partially reversed by c-Met upregulation (Fig. 8C and D). In addition, overexpression of c-Met could reverse the inhibitory effect of miR-409-3p mimics on the activities of migration and invasion in A549 cells (Fig. 8E and F). Therefore, these findings further indicate that c-Met is a functional target of miR-409-3p in LAD cells.

**Akt signaling mediates the downstream effects of miR-409-3p/c-Met in LAD cells**

Previously, it has been reported that aberrant hepatocyte growth factor/Met signaling induces centrosome amplification via the Akt signaling pathway [18], we then explore...
whether miR-409-3p and c-Met mediated the regulation of malignant phenotypes of LAD cells by affecting the Akt signaling. First, we analyzed the effect of miR-409-3p and c-Met expression on phosphorylated c-Met (p-c-Met) in LAD cells, and showed that upregulation of miR-409-3p and downregulation of c-Met significantly inhibit p-c-Met protein expression in LAD cells (Fig. 9A). Also, both upregulation of miR-409-3p and downregulation of c-Met induced the inhibition of phosphorylated Akt (pAkt) protein expression but had no effects on the expression of total Akt protein in A549 cells (Fig. 9B). Then, we detect the expression of downstream targets of Akt signaling, including Bcl-2, Bax, MMP-2 and MMP-9. Likewise, we showed that both miRNA-409-3p mimics and shRNA/c-Met2 could inhibit the expression of Bcl-2 protein and increase the expression of Bax protein, which induced the decreased ratio of Bcl-2/Bax (Fig. 9C). Also, the expression of MMP-2 and MMP-9 proteins was observed to be significantly downregulated in both miR-409-3p mimics and shRNA/c-Met2-transfected cells (Fig. 9D). Those targets of Akt signaling was correlated with growth and metastasis of LAD cells, so miR-409-3p might affect phenotypes of LAD cells via regulation of those
targets. Therefore, it was concluded that miR-409-3p inhibited growth, increased apoptosis and reduced invasion of LAD cells via inactivation of Akt signaling by targeting c-Met.

**c-Met is upregulated and inversely correlated with miR-409-3p expression in human LAD tissues**

To further examine the role of c-Met in LAD development, c-Met protein was detected in 34 cases of paired non-cancerous tissue (N) and LAD (T) tissue samples by Western blotting assay. The mean level of c-Met protein in LAD tissues was significantly higher than that in non-cancerous tissues ($P=0.0054$; Fig. 10A and B). Next, we investigated whether c-Met protein expression was inversely correlated with levels of miR-409-3p in LAD tissues. A total of 34 LAD tissues were analyzed for the expression levels of c-Met and for miR-409-3p expression. A statistically significant inverse correlation was observed between c-Met and miR-409-3p ($r= -0.416; P=0.026$, Pearson’s correlation; Fig. 10C). Therefore, these data further supported that downregulation of miR-409-3p was inversely correlated with overexpression of c-Met in LAD tissues.

**Discussion**

Emerging evidence has shown that dysregulation of miRNAs plays critical roles in tumorigenesis and the functions of miRNAs are complicated because they can downregulate numerous target genes including tumor suppressors and oncogenes [19]. Thus, it is necessary to explore their roles in tumor development. In the present study, we showed for the first time that miR-409-3p was significantly downregulated in LAD and an independent prognostic factor for patients. Functional analyses indicated that miR-409-3p
could inhibit growth, induce apoptosis and reduce invasion in LAD cells via inactivation of Akt signaling by targeting c-Met. These data indicates that miR-409-3p may be a novel tumor suppressor which plays fundamental roles in lung carcinogenesis.

The pathogenesis of LAD involves multiple factors, including genetic predisposition, epigenetic regulation and environmental interaction [20]. The recent discovery of miRNAs and their epigenetic regulation add further complexity to human diseases and are attached more importance. Recently, correlations of aberrant expression of miRNAs and growth, metastasis and chemo- or radioresistance of LAD are increasingly reported. Kitamura et al showed that miR-134/487b/655 cluster could regulate TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells [21]. Zhao and his colleagues reported that downregulation of miR-145 might contribute to lung adenocarcinoma cell growth to form brain metastases [22]. Xiang et al showed that microRNA-98 could sensitize cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMG2 [23]. Liu and his colleagues reported that microRNA-449a could enhance radiosensitivity in CL1-0 lung adenocarcinoma cells [24]. However, the roles of miR-409-3p in LAD progression remain unclear and need to be further elucidated. First, we analyzed the correlation of miR-409-3p expression with clinicopathologic factors of LAD patients, and showed that the expression of miR-409-3p was closely correlated with tumor differentiation, pTNM stage and lymph node metastasis and poor survival of LAD patients. Further functional analysis indicated that transfection of miR-409-3p mimics could inhibit growth, induce apoptosis and inhibit migration or invasion in LAD cell. These data suggest that miR-409-3p functions as a tumor suppressor in LAD cells. Consistent with our work, other groups have reported that miR-409-3p functions as a tumor suppressor in gastric cancer. Zheng and his colleagues showed that microRNA-409-3p could suppress tumour cell invasion and metastasis by directly targeting radixin in gastric cancers [14]. Also, Li et al reported that microRNA-409-3p could regulate cell proliferation and apoptosis by targeting PHF10 in gastric cancer [25]. In bladder cancer, microRNA-409-3p is reported to inhibit migration and invasion of bladder cancer cells via targeting c-Met [13]. Moreover, miR-409-3p can inhibit HT1080 cell proliferation, vascularization and metastasis by targeting angiogenin [15]. In this report, we have, for the first time, established the role of miR-409-3p in LAD growth and invasion. Our findings, together with other results, indicated that miR-409-3p might function as a tumor suppressor in human cancers. Interestingly, Nadal and his groups identified a microRNA cluster at 14q32 drives aggressive lung adenocarcinoma, and further confirmed that eleven of 22 miRNAs associated with poor survival were encoded in a large microRNA cluster at 14q32, including 3 miRNAs encoded at 14q32 (miR-411, miR-370, and miR-376a) [26]. Although it is also originated from the chromosome 14q32 region, it acts as a tumor suppressor in LAD cells. However, little is known about the underlying molecular mechanisms of miR-409-3p in human LAD.

c-MET is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte growth factor, activates a wide range of different cellular signaling pathways, including Akt signaling pathway [27]. To date, c-Met has been well-established as playing critical roles in growth, motility, migration and invasion [28, 29]. c-Met has also been found to be aberrantly activated in human cancers via mutation, amplification or protein overexpression [30]. Previous study has reported that activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line [31]. Also, Stabile and his colleagues reported that transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer [32]. Interestingly, it is found that HGF/c-MET system constitutes an autocrine activation loop in cancer-stromal myofibroblasts and this autocrine system may play a role in invasion and metastasis of lung adenocarcinoma [33]. Subsequent study shows that c-Met is directly downregulated by miR-449a, which inhibits growth and invasion of non-small cell lung cancer cells [34]. As one mRNA can be potentially regulated by multiple miRNAs [35], whether c-Met can be regulated by other miRNAs in human LAD needs to be further elucidated. In the present study, we confirmed that c-Met was a direct and functional target of miR-409-3p. A negative correlation between miR-409-3p
and c-Met expression was observed in clinical LAD tissue samples. Transfection of miR-409-3p mimics led to the decreased expression of c-Met protein in LAD cells, while transfection of miR-409-3p inhibitor induced the increased expression of c-Met protein. Luciferase activity assay indicated that miR-409-3p could bind to the 3′-UTR sequence of c-Met mRNA. Further functional studies indicated that siRNA-mediated c-Met downregulation could mimic the tumor suppressor roles of miR-409-3p and overexpression of c-Met could partially rescue the effects of miR-409-3p mimics on malignant phenotypes of LAD cells. Furthermore, we found that both upregulation of miR-409-3p and downregulation of c-Met could inactivate the Akt signaling and affect the expression of downstream effectors. Our data showed that miR-409-3p mimics and siRNA/c-Met could downregulate the expression of phosphorylated Akt protein, which eventually induced the decreased expression of Bcl-2, MMP-2 and MMP-9 and the increased expression of Bax. The changes of those downstream effectors lead to growth inhibition, apoptosis enhancement and suppression of migration and invasion in LAD cells. Collectively, the downregulation of miR-409-3p in LAD may contribute to tumor growth and invasion, at least in part, via the upregulation of c-Met. Of course, this study has several limitations. First, while a single miRNA can target many genes, so other miRNA target validations should be performed in future researches. Second, further investigation of other LAD cell lines is needed to confirm the clinical significance of miR-409-3p in human LAD. Third, phenotypic analyses from pooled transfectants were performed, and phenotypic separation followed by differential expression analyses of miR409-3p and c-Met expression should be performed.

In conclusion, the present study shows for the first time that miR-409-3p is downregulated in LAD and may be an independent poor prognostic factor for patients. MiR-409-3p possesses the potency to inhibit LAD growth, migration and invasion via regulation of Akt signaling pathway by targeting c-Met. The newly identified miR-409-3p/c-Met axis provides a novel insight into the pathogenesis of LAD, and provides us a wider perspective on LAD intervention and treatment.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (No.81272601,81472198), the Key Clinical Medicine Technology Foundation of Jiangsu Province (No.BL2014096), the Medical Key Talented Person Foundation of the Jiangsu Provincial Developing Health Project (No.RC2011080), Innovation Team Project of the Second Affiliated Hospital of Nanjing Medical University and "333 high class Talented Man Project" (No.2011-III-2630).

References